Get the Stockscreener App
0.7799
6.61%
0.0567
Estrella Immunopharma Inc stock is traded at $0.7799, with a volume of 84,134.
It is up +6.61% in the last 24 hours and down -8.21% over the past month.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
See More
Previous Close:
$0.7232
Open:
$0.735
24h Volume:
84,134
Relative Volume:
2.18
Market Cap:
$32.60M
Revenue:
-
Net Income/Loss:
$-13.25M
P/E Ratio:
-2.2075
EPS:
-0.3533
Net Cash Flow:
$-8.02M
1W Performance:
+6.79%
1M Performance:
-8.21%
6M Performance:
-39.77%
1Y Performance:
-15.27%
1-Day Range:
$0.7201
$0.85
1-Week Range:
$0.69
$0.85
52-Week Range:
$0.6781
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Name
Estrella Immunopharma Inc
Sector
Industry
Phone
(510) 318-9098
Address
5858 HORTON STREET, SUITE 370, EMERYVILLE
Compare ESLA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.7575 | 31.12M | 0 | -13.25M | -8.02M | -0.3533 |
VRTX
Vertex Pharmaceuticals Inc
|
515.31 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.34 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.54 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.30 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Estrella Immunopharma Inc Stock (ESLA) Latest News
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella Immunopharma Inc. (NASDAQ: ESLA) Share Price, ESLA Stock News, ESLA Share Price & Updates - Kalkine
Estrella Immunopharma (ESLA): Armistice Capital discloses 4.99% ownership stake - Stock Titan
Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary - TradingView
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella adds fourth site to EB103 lymphoma trial - Investing.com
Estrella Immunopharma Inc (ESLA) Stock News Today - TradingKey
Estrella Immunopharma (ESLA) Stock Price, News & Analysis - MarketBeat
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Estrella Immunopharma (ESLA) Rallies 6.11% as CAR T-Cell Focus Draws Investor AttentionTotal Put Call - dars.gov.et
Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - tradingview.com
Estrella adds third site to EB103 lymphoma trial - Investing.com
Estrella adds third site to EB103 lymphoma trial By Investing.com - Investing.com South Africa
Estrella Immunopharma (ESLA) Holds at $0.71 as Downside Pressures Remain ContainedTRIN Signal - dars.gov.et
Price to sales forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella activates second site for EB103 lymphoma trial By Investing.com - Investing.com Canada
Estrella activates second site for EB103 lymphoma trial - Investing.com
Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Balance Sheet - TradingKey
Estrella Immunopharma Inc (ESLA) Cash Flow - TradingKey
Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.750|Chg%:-0.030 - TradingKey
TradingKey - TradingKey
Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ESLA|Estrella Immunopharma Inc|Price:0.780| - TradingKey
Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Estrella doses first patient in EB103 trial expansion phase - Investing.com
Estrella doses first patient in EB103 trial expansion phase By Investing.com - Investing.com Canada
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma - Yahoo Finance
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Estrella Immunopharma, Inc. (ESLA) stock price, news, quote and history - Yahoo Finance UK
Estrella Immunopharma Inc. (ESLA) Q2 2026 Earnings: Wider-than-Expected Loss Despite Double-Digit Stock RallyConsensus Forecast Report - dars.gov.et
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
Estrella Immunopharma Warrants (ESLAW) Slide 7.5% as Support and Resistance Converge at $0.08Factor Crowding - dars.gov.et
Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView
ESLA Navigates Biotech Headwinds: Estrella Immunopharma Tests Support at $0.93Volume Dry Up - dars.gov.et
Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView
Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.10 Amid Low VolatilityCalendar Spread Trade - dars.gov.et
Investigation launched into Estrella Immunophar... - Pluang
AGIG: Abbott Cooper PLLC Announces Investigation on Behalf of Abundia Global Impact Group, Inc. (Formerly Houston American Energy Corp.) Stockholders - GlobeNewswire Inc.
ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders - GlobeNewswire
Estrella Immunopharma Inc Stock (ESLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Estrella Immunopharma Inc Stock (ESLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Xu Jiandong | Chief Financial Officer |
Sep 22 '25 |
Buy |
1.16 |
1,000 |
1,160 |
16,700 |
| Xu Jiandong | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.04 |
100 |
104 |
264,588 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):